Artrya Secures $0.3M U.S. Contract with Northeast Georgia Health System
Artrya Limited has landed a significant three-year commercial agreement with Northeast Georgia Health System, marking its second U.S. customer for the AI-powered Salix platform. This deal accelerates Artrya’s footprint in cardiovascular diagnostics across a major U.S. health network.
- Three-year US$0.3 million commercial agreement with Northeast Georgia Health System
- Salix platform integrated into clinical workflow across five hospitals and outpatient centers
- Fee-per-scan revenue model for Plaque module; Flow module pending FDA clearance
- New Atlanta-based Customer Success team to support rollout and clinician engagement
- Agreement strengthens Artrya’s U.S. expansion and commercial validation strategy
Artrya’s U.S. Expansion Gains Momentum
Artrya Limited (ASX – AYA), an Australian medical technology company specialising in AI-driven cardiovascular diagnostics, has announced a pivotal commercial agreement with Northeast Georgia Health System (NGHS). This marks Artrya’s second U.S. commercial customer and represents a key milestone in its strategy to embed its Salix platform into clinical workflows across major health networks.
The three-year contract, valued at a minimum of US$0.3 million, licenses the Salix Coronary Anatomy platform as a software-as-a-service (SaaS) solution. Additionally, Artrya will generate fee-per-scan revenue from its Salix Coronary Plaque module, with plans to activate the Salix Coronary Flow module following FDA clearance. This layered revenue model underscores the company’s approach to scalable, recurring income streams.
Integration Into Clinical Practice
NGHS, a not-for-profit health network serving over 1.6 million patient visits annually, will deploy Salix across its five hospitals and outpatient centers, including the Georgia Heart Institute; one of the largest cardiology programs in Georgia. The platform’s integration with existing Picture Archiving and Communication Systems (PACS) and Electronic Medical Records (EMR) ensures seamless adoption into clinicians’ daily workflows.
Leaders at Georgia Heart Institute highlighted the transformative potential of Salix. Dr. Mudassar Ahmed, Chief Cardiology Officer, emphasised how the platform supports earlier risk identification and proactive treatment strategies, while Dr. Zaid Said, Medical Director of Cardiac CT and MRI, noted that Salix streamlines interpretation and reduces variability, delivering actionable insights at the point of care.
Supporting Growth with Local Expertise
To facilitate this rollout, Artrya has established a Customer Success team based in Atlanta. This team will provide technical integration, clinician training, and ongoing support, reflecting the company’s commitment to ensuring smooth adoption and maximising clinical impact.
Looking ahead, Artrya is preparing its FDA submission for the Salix Coronary Flow module, which will expand its product offering and unlock additional reimbursement opportunities under Category 1 CPT codes. This regulatory milestone will be critical in broadening the platform’s clinical utility and commercial appeal.
Overall, this agreement not only validates Artrya’s technology in a real-world clinical setting but also strengthens its commercial foundation in the competitive U.S. cardiovascular diagnostics market.
Bottom Line?
Artrya’s growing U.S. partnerships and upcoming FDA milestones position it for accelerated adoption and revenue growth in cardiovascular AI diagnostics.
Questions in the middle?
- When will the Salix Coronary Flow module receive FDA clearance and how will it impact revenue?
- How quickly will NGHS scale Salix usage across its network and what adoption challenges might arise?
- What are Artrya’s plans to convert its remaining U.S. foundation partners into commercial customers?
